Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child

Pediatric Hematology and Oncology

Volumn 31, Issue 2, 2014, Pages 143-148

  Rock, Nathalie ^a   Mattiello, V ^a   Judas, C ^a   Huezo Diaz, P ^a,b   Bourquin, J P ^c   Gumy Pause, F ^a,b   Ansari, M ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; Children; Relapse

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE; RETINOIC ACID;

CASE REPORT; CHILD; FEMALE; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECURRENT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CHILD; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; RECURRENCE; TRETINOIN;

EID: 84894463973     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2013.876470     Document Type: Article

References (22)

1. Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematologica. 2008;119:73-82
2. Yoo ES. Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr. 2011;54:95-105
3. Lengfelder E, Hofmann W-K, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26:433-442
4. Zhang X-W, Yan X-J, Zhou Z-R, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science (New York, N.Y.). 2010;328:240-243
5. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-Trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood . 2006;107:3469-3473
6. George B, Mathews V, Poonkuzhali B, et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: A single center experience. Leukemia. 2004;18: 1587-1590
7. Zhang L, Zhu X, Zou Y, et al. Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. Int J Hematol. 2011;93:199-205
8. Zhou J, Zhang Y, Li J, et al. Single-Agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115:1697-702
9. Zhang L, Zhao H, Zhu X, et al. Retrospective analysis of 65Chinese childrenwith acute promyelocytic leukemia: A single center experience. Pediatr Blood Cancer. 2008;51:210-215
10. Beccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031-1043
11. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acutepromyelocytic leukemia.N Engl J Med. 2013;369:111-121
12. Huang H, Qin Y, Xu R, et al. Combination therapy with arsenic trioxide, all-Trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leukemia Res. 2012;36:841-845
13. EbingerM, Schwarze CP, Feuchtinger T, et al. Long-Termremission after first-line single-Agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy. Pediatr Hematol Oncol. 2011;28:334-337
14. Fox E, Razzouk BI,Widemann BC, et al. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008;111:566-573
15. Au WY, Li C, Lee V, et al. Oral Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia in Pediatric Patients. Pediatr Blood Cancer. 2012;58:630-632
16. Visani G, Piccaluga PP,Martinelli G, et al. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-Time quantification of minimal residual disease. Haematologica. 2003;88: ELT15
17. Jurcic J-G,Nimer S-D, ScheinbergD-A, et al. Prognostic significance of minimal residual disease detection and PML/RAR-A isoform type: Long-Term follow-up in acute promyelocytic leukemia. Blood 2001;98: 2651-2656
18. Zhou G-B, Zhang J, Wang Z-Y, et al. Treatment of acute promyelocytic leukaemia with alltrans retinoic acid and arsenic trioxide: A paradigm of synergistic molecular targeting therapy. Philosophical transactions of the Royal Society of London Series B, Biological Sci. 2007;362:959-971
19. Wang H, Chen X, Wang B, et al.The efficacy and safety of arsenic trioxide with or without all-Trans retinoic acid for the treatment of acute promyelocytic leukemia: A meta-Analysis. Leukemia Res. 2001;35:1170-1177
20. Soignet SL, Frankel SR,Douer D, et al. United StatesMulticenter Study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860
21. Breccia M, Lo-Coco F. Arsenic trioxide for managementof acute promyelocytic leukemia: Current evidence on its role in front-line therap and recurrent disease. Expert Opin Pharmacother. 2012;13(7):1031-1043
22. Bally C, Fadlallah J, LevergerG, et al.Outcome of acute promyelocytic leukemia in children and adolescents: Ananalysis intwoconsecutive trials ofTheEuropeanAPLGroup. JClinOncol. 30:1641-1646